Mepolizumab is a humanized monoclonal antibody that selectively targets interleukin-5 (IL-5), a cytokine involved in the growth, activation and survival of eosinophils. By binding to IL-5, mepolizumab reduces eosinophil production and survival and helps control eosinophil-driven inflammation.
Mepolizumab is used in the management of several eosinophilic inflammatory disorders, including severe eosinophilic asthma and other approved eosinophil-associated conditions.
Mepolizumab is a recombinant humanized IgG1 monoclonal antibody produced using recombinant DNA technology in mammalian cell culture. Unlike conventional small-molecule APIs, mepolizumab is a complex biological molecule with a three-dimensional protein structure and glycosylation profile.
The antibody has an approximate molecular mass of 149 kDa. As a biological API, its quality is assessed through multiple orthogonal analytical and biological methods rather than a single chemical assay.
Mepolizumab binds specifically to human IL-5 and prevents IL-5 from interacting with its receptor on eosinophils.
IL-5 is an important cytokine regulating eosinophil differentiation, maturation, activation and survival. Neutralization of IL-5 decreases eosinophil levels in blood and tissues, thereby reducing eosinophil-mediated inflammation.
Mepolizumab is used in approved biological formulations for several eosinophil-associated inflammatory diseases, including:
Approved indications, age groups and dosing requirements depend on the regulatory jurisdiction and product formulation.
Mepolizumab requires comprehensive biologics characterization and quality testing. Applicable testing may include identity, protein concentration, purity, aggregates, fragments, charge variants, glycosylation profile, biological activity, host-cell proteins, residual host-cell DNA, residual process-related impurities, endotoxin, bioburden and sterility, as applicable to the specific drug substance or finished product.
Orthogonal analytical techniques such as chromatography, electrophoresis, mass spectrometry, peptide mapping and cell-based biological assays may be used to characterize the antibody.
Final acceptance criteria should follow the applicable manufacturer's validated specification and Certificate of Analysis.
Mepolizumab biological material should generally be maintained under refrigerated, controlled conditions and protected from freezing and excessive light.
Because storage requirements can differ between drug substance and finished dosage forms, the manufacturer's approved storage specification should always be followed.
Mepolizumab may be supplied for qualified pharmaceutical development, biologics manufacturing, formulation development, analytical and research applications, subject to applicable regulatory and quality requirements.
Mepolizumab is a specialized biological API intended for qualified pharmaceutical and biotechnology applications. Product documentation may include specifications, Certificate of Analysis, analytical characterization data, quality documentation and packaging information according to applicable requirements.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 5.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 5.0% |